The Impact of Underinsurance on Bladder Cancer Diagnosis, Survival, and Care Delivery
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
Fletcher, Sean A.
MetadataShow full item record
CitationFletcher, Sean A. 2019. The Impact of Underinsurance on Bladder Cancer Diagnosis, Survival, and Care Delivery. Doctoral dissertation, Harvard Medical School.
AbstractPurpose: Health inequity in the United States are closely linked to patients’ ability to afford their care. We sought to determine the association between underinsurance and outcomes in bladder cancer, a disease that confers a substantial financial burden upon diagnosed individuals.
Methods: We used the Surveillance, Epidemiology, and End Results (SEER) registry and National Cancer Database (NCDB) to identify individuals aged <65 years who were diagnosed with bladder cancer from 2007 to 2014. We evaluated the association between insurance status and outcomes related to prognosis (diagnosis with advanced disease, cancer-specific survival) and care delivery (delay in care, treatment in a high-volume hospital, and receipt of neoadjuvant chemotherapy).
Results: Compared to those with private insurance, uninsured and Medicaid-insured individuals were nearly twice as likely to receive a diagnosis of muscle-invasive bladder cancer (Uninsured OR: 1.90; 95% CI: 1.70 – 2.12. Medicaid OR: 2.03; 95% CI: 1.87 – 2.20). These groups were also more likely to die of bladder cancer (Uninsured adjusted hazard ratio [AHR]: 1.49; 95% CI: 1.31 – 1.71. Medicaid AHR: 1.61; 95% CI: 1.46 – 1.79). Delays in treatment > 90 days were more likely for the uninsured (OR: 1.36; 95% CI: 1.12 – 1.65) and Medicaid-insured (OR: 1.22; 95% CI: 1.03 – 1.44) compared to the private-insured. Uninsured patients had lower odds of treatment in a high-volume facility (OR: 0.66; 95% CI: 0.52 – 0.83), and Medicaid-insured patients had lower odds of receiving neoadjuvant chemotherapy (OR: 0.74; 95%CI: 0.60 – 0.91).
Conclusions: Uninsured and Medicaid-insured individuals are more likely than those with private insurance to be diagnosed with advanced bladder cancer as well as die from the disease; they are also subject to poorer care quality. Expanding high-quality insurance coverage to marginalized populations may help to reduce the burden of this disease.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:42069189